Ten patients 3 cases of abscess of vaginal cu, 1 case of abscess of vaginal cu complicated with parametritis, 2 cases of pyosalpinx, 1 case each of abscess of abdominal wall, pelvic cellulitis, pyometra with cervical cancer and paraovarian abscess were treated with cefuzonam (CZON), which was administrated by intravenous drip infusion at a dose of 1,000 mg twice a day for 3 to 10 days (6 g to 19 g total). The clinical e ectiveness reached 70.0% including 1 excellent case, 6 good cases and 3 poor cases. Bacteria were detected in all the 10 cases, and with CZON treatment, bacterial eradication were obtained in 3 cases, bacteria decreased in 3 cases, no change in 2 cases and bacterial replacement occurred in 2 cases.
No abnormal laboratory findings and side e ects were noted. From the above results, CZON seemed to be a highly e ective and useful agent for gynecological infections.

View full abstract

The distribution of the new cephem antibiotic, cefuzonam (CZON) into adnexa uteri and uterine tissues, and clinical efficacy on patients with obstetric and gynecologic infections were studied. The results obtained are summarized as follows.
1. Concentrations of CZON in arterial and venous blood, oviduct, ovary, endometrium, myometrium, cervix uteri and portio vaginalis tissues were measured. The results demonstrated good transfer of the drug into various internal genital organs.
2. In clinical studies, CZON was given to 5 cases with various infections such as pyometra, acute vulvitis, pelvic peritonitis, pyelonephritis and puerperal intrauterine infection. Clinical efficacies were evaluated as excellent in 2 cases, and good in 3 cases. The efficacy rate was 100%.
No side effects were observed in any cases.
In laboratory tests, transient elevations of GOT, GPT and 7-GTP were observed in 1 case.
Therefore, it is concluded that CZON is a useful drug for various types of infections in the field of obstetrics and gynecology.

View full abstract

Antimicrobial activities of sulbactam/cefoperazone (SBT/CPZ) against 50 fresh clinical isolates of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter spp., Serratia marcescens, Proteus mirabilis, Proteus vulgaris and Pseudomonas aeruginosa were compared to those of CPZ, Cefotiam (CTM), Cefotaxime (CTX) and Latamoxef (LMOX). Minimal inhibitory concentrations (MIC's) of SBT and CPZ mixed in a ratio of 1: 1 were determined by the dilution method using MUELLER-HINTONa gar and expressed by absolute concentrations of CPZ.
Antimicrobial activities of SBT/CPZ against principally penicillinase (PCase) producing bacteria, i.e., S. aureus, E. coli, K. pneumoniae, P. mirabilis, were superior to those of CPZ alone. The presence of SBT in concentrations around 0.39-1.56μ clearly enhanced CPZ's antimicrobial activities against these PCase producing strains.
The synergistic antimicrobial effects of SBT in combination with CPZ were less pronounced against principally cephalosporinase (CEPase) producing bacteria, i.e., C. freundii, Enterobacter spp., S. marcescens, P. vulgaris, and P. aeruginosa, and exerted with SBT at concentrations around 3.13-12.5μ.
Comparative antimicrobial activities indicated by MICso's of tested agents showed that SBT/CPZ had more stable activities against bacteria ranging from Gram-positive to Gram-negative bacteria than CTM, CTX and LMOX.
MIC's of SBT/CPZ were higher than 25μ against 8% of S. aureus, 18% of C. freundii, 10% of Enterobacter spp., 26% of S. marcescens, 2% of P. vulgaris, and 18% of P. aeruginosa. These resistant strains against which the addition of SBT showed no synergism, may possess other mechanism of resistance than β-lactamase production.
It is concluded that the presence of CPZ resistant strains is an actual current problem and not an imaginary future problem, and that the number of resistant strains against other new cephems which have different chemical structure from CPZ is increasing.
When these present bacteriological environments are considered, the appearance of SBT/CPZ in the clinical practice is timely and meaningful.

View full abstract

Flomoxef (FMOX, 6315-S) is a new antibiotic of oxacephem group with a broad antibacterial spectrum. Seven patients were treated by intravenous instillation of 1 g of FMOX twice daily.
Seven-day treatment with FMOX was ineffective against chronic bronchitis caused by Escherichia coli in a patient who had received an operation for esophageal cancer 6 years previously. Seven-day treatment with FMOX was effective against acute pneumonia caused by Staphylococcus aureus in a patient with lung cancer. Nine-day treatment with FMOX was effective against pulmonary suppuration caused by Streptococcus pneumoniae in a patient with lung cancer. Six-day and 7-day treatment with FMOX were excellently or moderately effective against suspectable obstructive pneumonia in 2 patients with lung cancer. Five-day and 6-day treatment with FMOX were ineffective against fever of unknown origins in 2 patients with lung cancer.
Overall, FMOX was effective in 4 of the 7 patients evaluated.

View full abstract

Flomoxef (FMOX, 6315-S) was used in the treatment of 10 patients (male 8, female 2) with respiratory infections, and clinical responses and side effects of FMOX were evaluated. The mean age of the patients was 68.2 years, and the mean body weight was 45.8 kg; this background of the patients indicates that most of them were elderly, and light in body weight. FMOX was administrated by drip infusion in 1 g doses twice daily in all the cases. The mean duration of FMOX therapy was 14 days, and the mean total dose administered was 28g.
Efficacy rate was 80% in the 10 cases. Adverse reactions were not observed and no abnormalities in laboratory tests were detected. In conclusion, FMOX is an effective antibiotic in the treatment of aged patients with respiratory infections.

View full abstract

Laboratory and clinical studies were performed on a new oxacephem antibiotic, flomoxef (FMOX, 6315-S).
In vitro antibacterial activity of FMOX was evaluated in comparison to latamoxef (LMOX), cefmetazole (CMZ), cefazolin (CEZ) using clinically isolated strains of Gram-negative and Gram-positive bacteria. Antibacterial activities of FMOX were stronger than LMOX, CMZ, CEZ against Escherichia coli, Klebsiella but only slightly effective against Staphylococcus aureus. This antibiotic drug was administered to 5 patients consisting of 2 cases with pneumonia, one each with pyelonephritis, chronic bronchitis and urinary tract infection.
The drug was given in 1 g drip infusion twice a day for 8 to 13 days. Clinical efficacies of FMOX were excellent in 1 case, good in 2, fair in 1, and unevaluable in 1. As for bacteriological effect of FMOX, organisms were eradicated in 3 cases.
No side effect was noted and there was no abnormal change in laboratory findings.

View full abstract

Flomoxef (FMOX, 6315-S) was administered to 22 patients with respiratory tract infections. The patients consisted of 13 patients with pneumonia, 7 with bronchitis, 1 with bronchiectasis and 1 with pyothorax. The drug was administered by intravenous injection or intravenous drip infusion twice a day with doses of 1 to 2 g and total doses ranged from 17 to 64 g.
The following results were obtained.
1. Clinical responses to the therapy were excellent in 1 case, good in 10 cases, fair in 4 cases, poor in 4 cases and not determined in 3 cases. Efficacy ratio was 57.9%.
2. As for adverse reactions, exanthema in 1 patient and stomatitis and numbness of tongue in another patient were observed, but these symptoms improved with cessation of the therapy. Abnormal laboratory test values were observed in 5 cases.
From these results it appears that FMOX is a valuable antimicrobial agent against patients with respiratory tract infections.

View full abstract

Flomoxef (FMOX, 6315-S), a new antibacterial drug, was administered to 9 cases with respiratory tract infections for a duration of 8-16 days at a daily dose of 2.g. Diagnosis of these patients were bronchopneumonia 5 cases, chronic bronchitis 3 cases and acute bronchitis 1 case. From transtracheal aspiration several organisms were isolated; Haemophilus influenzae was isolated in 3 cases, Streptococcus pneumoniae in 3 cases, H. influenzae plus Branhamella catarrhalis in 1 case, Streptococcus dysgalactiae plus Neisseria meningitidis in 1 case and Corynebacterium pseudodiphtheriticum in 1 case.
The clinical efficacy was good in all 9 cases, the efficacy rate was 100%. All the bacteria were eliminated. Side effects were not observed.
From these results, it appears that FMOX is a valuable drug in the treatment of respiratory tract infections.

View full abstract

Clinical efficacy, bacteriological effect and safety of a new antibiotic flomoxef (FMOX, 6315-S) in respiratory infections were studied.
Efficacy of FMOX in 6 patients with infectious diseases including 2 cases with pneumonia, 3 cases with acute exacerbation by respiratory infection, 1 case with obstructive pneumonia were clinically evaluated.
Two strains of Haemophilus influenzae, 1 strain of Streptococcus pneumoniae and 1 strain of Staphylococcus aureus which were detected as causative organisms in 2 cases disappeared or decreased after treatment with FMOX.
Assessing both clinical and bacteriological findings, effects of FMOX were good in 5 cases and fair in 1 case. No adverse effects were observed in clinical or laboratory findings. Consequently, FMOX is considered to be a very useful antibiotic in the treatment for respiratory infectious diseases.

View full abstract

Flomoxef (FMOX, 6315-S) is a new oxacephem with a broad spectrum of antimicrobial activity. We used FMOX for treatment of 13 patients with respiratory tract infections including 4 cases of pneumonia, 5 of lung abscess and 4 of exacerbation of the chronic airway diseases.
FMOX showed excellent in vitro antimicrobial activities against clinical isolates including 4 strains of Streptococcus pneumoniae, 2 strains of Haemophilus influenzae and each one strain of Escherichia coli and Klebsiella pneumoniae. Clinical responses were excellent in 3 cases, good in 7 and fair or poor in 3.
No side effect was observed, but abnormal laboratory findings caused by FMOX administration were found in 2 cases; hypertransaminasemia and eosinophilia. However, neither of them was severe.
From the above results, it is considered that FMOX will be useful for treatment of patients with respiratory tract infections.

View full abstract

1. Bacteria detected in cases of acute abdominal ailments encountered in the first department of surgery at Hiroshima university and its related facilities during the recent 4 and a half years were reviewed and the antibacterial activities of flomoxef (FMOX, 6315-S) against these isolates were investigated. As a result, this antibiotic was found to show very high activities against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Klebsiella pneumoniae and Proteus spp.
2. One gram of FMOX dissolved in 100 ml of physiological saline was administered by intravenous drip infusion during operation and its concentrations in serum and intraperitoneal exudate were determined. The intraperitoneal exudate concentration exceeded the serum concentration in 2 hours after the completion of the drip infusion and, reached high enough concentration to be effective against susceptible bacteria with MICs about 12.5μg/ml.
The above results suggested that the new cephem antibiotic FMOX for injection should be sufficiently effective against acute peritonitis.

View full abstract

To women undergoing radical and total hysterectomy, flomoxef (FMOX, 6315-S) in a dose of 2 g was administered by intravenous drip infusion over 1 hour and drug concentrations in serum and pelvic dead space exudate as well as pelvic organs/tissues were determined over time.
The following results were obtained:
1. Serum concentrations of FMOX after intravenous infusion showed the peak value of 92.86+17.05 ig/ml at the end of infusion and then gradually decreased to 29.00+10.49 μg/ml in 1 hour and 1.16±1.08 μg/ml in 6 hours.
2. Concentrations in pelvic dead space exudate, which were 6.54+ 3.21μg/ml at the end of intravenous infusion, gradually increased to 31.28± 12.69μg/ml in 30 minutes, and the peak of 35.21+ 13.29μg/ml in 1 hour. Exudate concentrations gradually decreased to 11.10+ 6.64μg/ml at 6 hours after infusion.
3. The serum concentration at the ligature of uterine artery was 103.21±51.69 μg/ml. Among concentrations in pelvic organ/tissues 37.17±18.20μ/gig in uterine cervix was the highest, followed by 35.77-1-7.68μg/g in portio vaginalis, 26.35±14.15μg/g in tube, 21.62±12.15μg/g in ovary, 20.56±9.82μg/g in myometrium, and 16.45±8.10μg/g in endometrium, in this order.
4. From an analysis of the two-compartment model, the maximum serum concentration was 92.81μg/ml, which was very high. The time of 50% reduction of concentration in IS phase was 1.21 hours. In the pelvic dead space exudate, the maximum concentration was 32.381μ/ml and the time of 50% reduction was 2.44 hours. The AUC was 147μg·hr/ml in serum and 201μg·hr/ml in the pelvic dead space. The shift to the pelvic dead space was 137% when AUC's were used as the basis of the comparison.
5. Clinically, FMOX was excellently effective against adnexitis caused by Peptostreptococcus asaccharolyticus, intrauterine infection caused by Staphylococcus aureus, cystitis caused by Klebsiella and Escherichia coli, vaginal stump infection caused by Streptococcus and E. coli and many other infections.

View full abstract

Flomoxef (FMOX, 6315-S) is a new oxacephem antibiotics chemically related to latamoxef.
Clinical studies on FMOX were carried out in the field of obstetrics and gynecology.
A total of 9 patients comprising 4 cases of endometritis, 4 of BARTHOLIN'S abscess and 1 of vulvar abscess were treated with FMOX using intravenous injection at a dose of 1 g twice daily for 5-6 days.
The clinical efficacy was good in all cases. Neither adverse reactions nor abnormal laboratory values were observed in any of the cases.
From the results, it was concluded that FMOX was an useful antibiotic in the field of obstetrics and gynecology.

View full abstract

Flomoxef (6315-S, FMOX), a new oxacephem antibiotic was studied clinically in 27 patients with complicated urinary tract infections.
FMOX was intravenously administered at a dose of 1.0 g twice daily for 5 days.
Clinical effect of FMOX on patients with complicated urinary tract infections were excellent in 11.5%, moderate in 57.7% and overall clinical efficacy rate was 69.2%. During the treatment with FMOX, urticaria was observed in 1 case.
In laboratory tests, a decrease of RBC, Hb and Ht in 1 case, a decrease of WBC in 1 case and an elevation of GPT in another case were observed. But these abnormal values were slight and transient.

View full abstract